Alumis (ALMS) Non-Current Deferred Tax Liability (2025)

Alumis' (ALMS) quarterly Non-Current Deferred Tax Liability came in at $2.1 million in Q4 2025, little changed on a QoQ basis from $2.1 million in Q3 2025.

Alumis (ALMS) Non-Current Deferred Tax Liability (2025) Analysis & Trends

Alumis (ALMS) has 1 years of Non-Current Deferred Tax Liability data on file, last reported at $2.1 million in Q4 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $2.1 million in Q4 2025; TTM through Dec 2025 was $2.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $2.1 million, changed N/A from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 stood at $2.1 million, roughly flat from $2.1 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for ALMS reached as high as $2.1 million in Q2 2025 and fell as low as $2.1 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Alumis 2.41 Bn 2.10 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 2.14 Mn
Dec 31, 2025 2.14 Mn
Sep 30, 2025 2.14 Mn
Sep 30, 2025 2.14 Mn
Jun 30, 2025 2.14 Mn
Jun 30, 2025 2.14 Mn